Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study

Andrii R Korol,1 Oleksandra Zborovska,2 Taras Kustryn,1 Oleksandra Dorokhova,2 Nataliya Pasyechnikova3 1Laser Department, 2Department of Inflammatory Pathology of the Eye, 3Filatov Institute of Eye Diseases and Tissue Therapy, National Academy of Medical Sciences of Ukraine, Odess...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Korol AR, Zborovska O, Kustryn T, Dorokhova O, Pasyechnikova N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Aflibercept angiogenesis inhibitors choroidal neovascularization central chorioretinitis anti-VEGF Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/bc733aecadca4690bf5eb8910fdd6d2a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bc733aecadca4690bf5eb8910fdd6d2a
record_format	dspace
spelling	oai:doaj.org-article:bc733aecadca4690bf5eb8910fdd6d2a2021-12-02T07:15:54ZIntravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study1177-5483https://doaj.org/article/bc733aecadca4690bf5eb8910fdd6d2a2017-07-01T00:00:00Zhttps://www.dovepress.com/intravitreal-aflibercept-for-choroidal-neovascularization-associated-w-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Andrii R Korol,1 Oleksandra Zborovska,2 Taras Kustryn,1 Oleksandra Dorokhova,2 Nataliya Pasyechnikova3 1Laser Department, 2Department of Inflammatory Pathology of the Eye, 3Filatov Institute of Eye Diseases and Tissue Therapy, National Academy of Medical Sciences of Ukraine, Odessa, Ukraine Purpose: The purpose of this study was to evaluate the potential benefits of intravitreal aflibercept injections for the treatment of choroidal neovascularization (CNV) secondary to chorioretinitis.Methods: In this uncontrolled, prospective cohort study, 15 eyes of 14 consecutive patients affected by CNV associated with ocular toxoplasmosis were treated with intravitreal aflibercept (2 mg) pro re nata and observed over a 12-month follow-up period. The primary outcome was the change in best-corrected visual acuity (BCVA) from baseline to month 12. Secondary outcomes included change in central retinal thickness (CRT) in the foveal area on optical coherence tomography (OCT) from baseline to month 12, the number of intravitreal aflibercept injections administered, and safety.Results: Mean (standard deviation [SD]) BCVA improved significantly from 0.36 (0.23) at baseline to 0.64 (0.3) at month 12 (P=0.0002). Mean (SD) CRT on OCT showed a reduction from 317 (74) µm at baseline to 254 (43) µm (P=0.0002) at month 12. A mean (SD) of 1.7 (0.5) injections (range, 1–2 injections) were performed during the study period. No cases of endophthalmitis, uveitis, stroke, or retinal detachment were noted. No patient demonstrated an intraocular pressure >20 mmHg at any study visit.Conclusion: Intravitreal aflibercept showed a positive clinical effect and was well tolerated for the treatment of CNV associated with chorioretinitis. The results could be helpful for selecting a treatment for CNV secondary to chorioretinitis. Keywords: aflibercept, angiogenesis inhibitors, choroidal neovascularization, central chorioretinitis, anti-VEGF, toxoplasmosisKorol ARZborovska OKustryn TDorokhova OPasyechnikova NDove Medical PressarticleAfliberceptangiogenesis inhibitorschoroidal neovascularizationcentral chorioretinitisanti-VEGFOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 11, Pp 1315-1320 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Aflibercept angiogenesis inhibitors choroidal neovascularization central chorioretinitis anti-VEGF Ophthalmology RE1-994
spellingShingle	Aflibercept angiogenesis inhibitors choroidal neovascularization central chorioretinitis anti-VEGF Ophthalmology RE1-994 Korol AR Zborovska O Kustryn T Dorokhova O Pasyechnikova N Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study
description	Andrii R Korol,1 Oleksandra Zborovska,2 Taras Kustryn,1 Oleksandra Dorokhova,2 Nataliya Pasyechnikova3 1Laser Department, 2Department of Inflammatory Pathology of the Eye, 3Filatov Institute of Eye Diseases and Tissue Therapy, National Academy of Medical Sciences of Ukraine, Odessa, Ukraine Purpose: The purpose of this study was to evaluate the potential benefits of intravitreal aflibercept injections for the treatment of choroidal neovascularization (CNV) secondary to chorioretinitis.Methods: In this uncontrolled, prospective cohort study, 15 eyes of 14 consecutive patients affected by CNV associated with ocular toxoplasmosis were treated with intravitreal aflibercept (2 mg) pro re nata and observed over a 12-month follow-up period. The primary outcome was the change in best-corrected visual acuity (BCVA) from baseline to month 12. Secondary outcomes included change in central retinal thickness (CRT) in the foveal area on optical coherence tomography (OCT) from baseline to month 12, the number of intravitreal aflibercept injections administered, and safety.Results: Mean (standard deviation [SD]) BCVA improved significantly from 0.36 (0.23) at baseline to 0.64 (0.3) at month 12 (P=0.0002). Mean (SD) CRT on OCT showed a reduction from 317 (74) µm at baseline to 254 (43) µm (P=0.0002) at month 12. A mean (SD) of 1.7 (0.5) injections (range, 1–2 injections) were performed during the study period. No cases of endophthalmitis, uveitis, stroke, or retinal detachment were noted. No patient demonstrated an intraocular pressure >20 mmHg at any study visit.Conclusion: Intravitreal aflibercept showed a positive clinical effect and was well tolerated for the treatment of CNV associated with chorioretinitis. The results could be helpful for selecting a treatment for CNV secondary to chorioretinitis. Keywords: aflibercept, angiogenesis inhibitors, choroidal neovascularization, central chorioretinitis, anti-VEGF, toxoplasmosis
format	article
author	Korol AR Zborovska O Kustryn T Dorokhova O Pasyechnikova N
author_facet	Korol AR Zborovska O Kustryn T Dorokhova O Pasyechnikova N
author_sort	Korol AR
title	Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study
title_short	Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study
title_full	Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study
title_fullStr	Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study
title_full_unstemmed	Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study
title_sort	intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/bc733aecadca4690bf5eb8910fdd6d2a
work_keys_str_mv	AT korolar intravitrealafliberceptforchoroidalneovascularizationassociatedwithchorioretinitisapilotstudy AT zborovskao intravitrealafliberceptforchoroidalneovascularizationassociatedwithchorioretinitisapilotstudy AT kustrynt intravitrealafliberceptforchoroidalneovascularizationassociatedwithchorioretinitisapilotstudy AT dorokhovao intravitrealafliberceptforchoroidalneovascularizationassociatedwithchorioretinitisapilotstudy AT pasyechnikovan intravitrealafliberceptforchoroidalneovascularizationassociatedwithchorioretinitisapilotstudy
_version_	1718399538248548352

Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study

Ejemplares similares